Email ID
Password
Scrip   
NovaBiotics nears licensing deal for topical antifungal candidate
20 November 2009
Sukaina Virji

The UK biotechnology company NovaBiotics is shortly to complete a Phase IIa trial of its topical fungal nail infection treatment, Novexatin (NP213).

The data are expected to seal a licensing deal for the product in the early part of next year. NovaBiotics has signed CDAs (confidential disclosure...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36